Trial
NCT03318939
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Spectrum Pharmaceuticals, Inc
Collaborators
—
Condition
NSCLC
Intervention
Poziotinib
Why stopped
Strategic business decision (unrelated to safety)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-12